136 related articles for article (PubMed ID: 11084176)
1. Randomized comparison of intranasal and transdermal estradiol.
Lopes P; Merkus HM; Nauman J; Bruschi F; Foidart JM; Calaf J
Obstet Gynecol; 2000 Dec; 96(6):906-12. PubMed ID: 11084176
[TBL] [Abstract][Full Text] [Related]
2. Intranasal versus transdermal matrix oestrogen replacement in Australasian women.
Davis SR; Davison SL; Wilson S; Shepherd J; Lawton B
Maturitas; 2005 Jun; 51(2):163-71. PubMed ID: 15917157
[TBL] [Abstract][Full Text] [Related]
3. Aerodiol versus the transdermal route: perspectives for patient preference.
Lopes P; Rozenberg S; Graaf J; Fernandez-Villoria E; Marianowski L
Maturitas; 2001 Jun; 38 Suppl 1():S31-9. PubMed ID: 11390122
[TBL] [Abstract][Full Text] [Related]
4. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
6. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
Genazzani AR; Cappagli B; Ciaponi M
Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
9. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology.
Odabaşi AR; Yüksel H; Demircan SS; Kaçar DF; Culhaci N; Ozkara EE
J Postgrad Med; 2007; 53(4):221-7. PubMed ID: 18097108
[TBL] [Abstract][Full Text] [Related]
11. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
Palacios S
Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
[TBL] [Abstract][Full Text] [Related]
12. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.
Mattsson LA; Christiansen C; Colau JC; Palacios S; Kenemans P; Bergeron C; Chevallier O; Von Holst T; Gangar K
Am J Obstet Gynecol; 2000 Mar; 182(3):545-52. PubMed ID: 10739506
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
14. Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women.
Figueroa-Casas PR; Alfonsin A; Arrighi A; Bluvstein G; Del Castillo R; Goldsman T; Inglesi J; Itala J; Novelli J; Monti C
Maturitas; 1994 Dec; 20(2-3):139-44. PubMed ID: 7715465
[TBL] [Abstract][Full Text] [Related]
15. Estradiol-intranasal: a review of its use in the management of menopause.
Dooley M; Spencer CM; Ormrod D
Drugs; 2001; 61(15):2243-62. PubMed ID: 11772138
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
17. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
Baksu B; Baksu A; Göker N; Citak S
Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
Mizunuma H
Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
Sajtos B; Herold J; Winkler UH; Schindler AE
Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
